PT  - JOURNAL ARTICLE
AU  - Gordon, Debra
ED  - Pratley, Richard
TI  - Recent Data from LEAD
DP  - 2010 Dec 01
TA  - MD Conference Express
PG  - 18--19
VI  - 10
IP  - 9
4099  - http://mdc.sagepub.com/content/10/9/18.short
4100  - http://mdc.sagepub.com/content/10/9/18.full
AB  - In patients with diabetes, vascular conditions are responsible for the majority of morbidity, mortality, and cost that are attributed to the disease [Centers for Disease Control and Prevention. National Diabetes Fact Sheet. 2007]. The Liraglutide Effect and Action in Diabetes [LEAD; NCT00700817] trials are designed to evaluate the efficacy and safety of glucagon-like peptide-1 agonist compared with existing antidiabetic therapies.